Trials / Unknown
UnknownNCT05385809
A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer
A Retrospective Study of Sintilimab Combined With Chemotherapy in Conversion Therapy of Unresectable Locally Advanced or Stage IV Gastric Cancer/Gastroesophageal Junction Carcinoma
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study was an observational, non-interventional, multicenter retrospective study to evaluate the feasibility and safety of sintilimab combined with chemotherapy (SOX or PS) in the clinical practice of unresectable locally advanced or stage IV gastric cancer/gastroesophageal junction carcinoma.
Conditions
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2022-07-30
- Completion
- 2023-12-31
- First posted
- 2022-05-23
- Last updated
- 2022-11-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05385809. Inclusion in this directory is not an endorsement.